6 Analysts Have This to Say About Arvinas
Within the last quarter, Arvinas (NASDAQ:ARVN) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish…
HC Wainwright & Co. Reiterates Buy on Arvinas, Maintains $90 Price Target
HC Wainwright & Co. analyst Andrew Fein reiterates Arvinas (NASDAQ:ARVN) with a Buy and maintains $90 price target.
Guggenheim Downgrades Arvinas to Neutral
Guggenheim analyst Michael Schmidt downgrades Arvinas (NASDAQ:ARVN) from Buy to Neutral.
Why Cutera Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Monday’s Mid-Day Session
Gainers
CinCor Pharma, Inc. (NASDAQ: CINC) shares jumped 137% to $27.93 after AstraZeneca announced it will acquire the company for $26 per share in cash.
Stocks That Hit 52-Week Lows On Thursday
Thursday's session saw 329 companies set new 52-week lows.
Baidu To $180? Plus This Analyst Cuts PT On MacroGenics By 56%
Mizuho cut the price target on Baidu, Inc. (NASDAQ: BIDU) from $200 to $180. Mizuho analyst James Lee maintained the stock with a Buy rating. Baidu shares rose 2.5% to trade at $97.49 on Wednesday.
Where Arvinas Stands With Analysts
Within the last quarter, Arvinas (NASDAQ:ARVN) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish…
Abercrombie & Fitch To Rally 21%? Plus This Analyst Predicts $237 For Autodesk
Telsey Advisory Group raised the price target on Abercrombie & Fitch Co. (NYSE: ANF) from $25 to $27. Abercrombie & Fitch shares fell 1.2% to $22.34 in pre-market trading.
Barclays Maintains Overweight on Arvinas, Lowers Price Target to $70
Barclays analyst Peter Lawson maintains Arvinas (NASDAQ:ARVN) with a Overweight and lowers the price target from $90 to $70.
Arvinas’s ARV-471 Achieves Clinical Benefit Rate Of 38% In Breast Cancer Setting
Arvinas Inc (NASDAQ:ARVN) announced initial results from the Phase 2 cohort expansion portion of a phase 1/2 study with ARV-471 in…